OxemiaTM (Desidustat) is an oral tablet formulation that is the first-in-India alternative to injectable erythropoietin-stimulating agents (ESAs)
The company also reported the issuance of an additional U.S. patent covering the drug, and the filing of a continuation patent application intended to expand patent coverage to other facets of the drug
Expands AbbVie's neuroscience portfolio, adding first-in-class modulators of the synaptic vesicle protein 2A, including lead molecule SDI-118 currently in Phase 1b studies
Meteoric Biopharmaceuticals have made rapid strides in the development of enzymes, probiotics and veterinary health products. It is seeking opportunities to scale up its growth backed by cutting edge R&D. Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals spoke to Thomas C Thottathil on the way forward
Brinton Pharmaceuticals enters exclusive sales and distribution rights of Scholl foot care products including Krack cream
OmniActive seeks to improve lives by enhancing nutrition and wellness through science and innovation
Ovarian cancer is one of the most difficult cancers to treat. It is typically not detected until later stages, and about 70 percent of patients will have recurrence after an initial treatment, which is often fatal
Scientists worldwide have started employing wastewater analysis as an efficient and cost-effective approach for assessing the dynamics of the virus in a population. Several scientific methods are being developed to rapidly decode the message carried by sewage
Patients can use the wearable, non-invasive device to measure six body parameters including blood glucose, blood pressure, heart rate, blood oxygen, respiratory rate and 6-lead ECG, from the comfort of their home
State-of-the-art laboratory to support ingredient and specialty chemical innovation, product formulation application development and more sustainable solutions across Europe and beyond
Subscribe To Our Newsletter & Stay Updated
